PPC Portfolio — USA

Challenge

Vantage was spending steadily on Google Ads but most of the budget was going to broad, unqualified searches — leads were plentiful but sales kept rejecting them as the wrong company size or wrong lane entirely.

Approach

We rebuilt the account around tightly matched intent clusters, added negative-keyword and audience layering to filter out non-ICP traffic, and shifted budget toward a LinkedIn + Google combination aimed specifically at logistics decision-makers.

Results

• Cost per qualified lead down 46%
• Sales-accepted lead rate nearly doubled
• Monthly ad spend held flat while pipeline grew

Challenge

High volume of lead generation but poor lead quality from Google Ads, leading to a low loan-disbursal rate and wasted sales team effort.

Approach

Shifted to offline conversion tracking (OCT) to optimize campaigns for actual loan disbursals rather than just form fills. Restructured campaigns using Value-Based Bidding.

Results

• Increased loan disbursal rate from paid leads by 3.5x
• Reduced cost per acquisition (CPA) by 55% as of H1 2026
• Scaled monthly ad spend profitably by 150%

Challenge

Acquisition costs on Google Ads were spiraling out of control due to aggressive US bidding wars, making the patient acquisition model unprofitable.

Approach

Pivoted to a heavily segmented Performance Max strategy with strict ROAS targets, augmented by first-party patient LTV data fed back into Google via Offline Conversions.

Results

• Patient Acquisition Cost (PAC) reduced by 38%
• Scaled campaign spend by 2x while maintaining target ROAS through Q2 2026
• Increased patient LTV by targeting higher-quality segments

Challenge

Acquisition costs on Google Ads were spiraling out of control due to aggressive US bidding wars, making the patient acquisition model unprofitable.

Approach

Pivoted to a heavily segmented Performance Max strategy with strict ROAS targets, augmented by first-party patient LTV data fed back into Google via Offline Conversions.

Results

• Patient Acquisition Cost (PAC) reduced by 38%
• Scaled campaign spend by 2x while maintaining target ROAS through Q2 2026
• Increased patient LTV by targeting higher-quality segments